Biotica

biotica discovers and develops novel polyketide therapeutics to create new medicines for serious diseases. biotica’s r&d pipeline is focused on optimised polyketide therapeutics for high-value indications. biotica's compounds, generated using the proprietary novopt™ technology, have unique chemistry and differentiated properties. polyketides are the basis of more than 40 successful therapeutics in a wide range of diseases. they make excellent leads for drug discovery, with naturally high affinity to biologically relevant targets, including protein-protein interactions and other traditionally difficult targets. biotica has formed successful partnerships with leading pharmaceutical companies, most recently wyeth and gsk, based on its high-value projects. projects are selected on three key criteria: market potential, clinical validation of the target and biotica exclusivity.